SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : EntreMed (ENMD)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Epicenter who wrote (1473)2/10/1999 5:57:00 PM
From: Mao II  Read Replies (2) of 2135
 
Epicenter: Pardon me for butting in. But the issue raised by the BMY decision does not undercut Folkman's science. Rather, it points to problems in delivering that science in a practical and timely fashion. Timely, that is, in the context of BMY's needs. There are other issues as well. Did BMY feel jerked around by ENMD? Did the departure of Folkman's big booster at BMY play a part in their withdrawal? What pressures -- either internally or from shareholders -- is BMY under that might compel a focus on shorter-term, more doable projects? None of these issues -- and they are serious ones -- reflect on Folkman. On the hype issue, you might want to consider the role of the NY Times and Gina K. Conversely, on the bashing side, you might want to look to the WSJ. What has been the impact of their rivalry on ENMD? Regards, M2
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News